JP2018516932A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516932A5
JP2018516932A5 JP2017562678A JP2017562678A JP2018516932A5 JP 2018516932 A5 JP2018516932 A5 JP 2018516932A5 JP 2017562678 A JP2017562678 A JP 2017562678A JP 2017562678 A JP2017562678 A JP 2017562678A JP 2018516932 A5 JP2018516932 A5 JP 2018516932A5
Authority
JP
Japan
Prior art keywords
amino
sulfonyl
phenyl
pyridine
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017562678A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516932A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/000821 external-priority patent/WO2016193812A1/en
Publication of JP2018516932A publication Critical patent/JP2018516932A/ja
Publication of JP2018516932A5 publication Critical patent/JP2018516932A5/ja
Pending legal-status Critical Current

Links

JP2017562678A 2015-06-02 2016-05-25 置換ピリジンおよび使用方法 Pending JP2018516932A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562169881P 2015-06-02 2015-06-02
US62/169,881 2015-06-02
PCT/IB2016/000821 WO2016193812A1 (en) 2015-06-02 2016-05-25 Substituted pyridines and method of use

Publications (2)

Publication Number Publication Date
JP2018516932A JP2018516932A (ja) 2018-06-28
JP2018516932A5 true JP2018516932A5 (cg-RX-API-DMAC7.html) 2019-06-27

Family

ID=57440295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017562678A Pending JP2018516932A (ja) 2015-06-02 2016-05-25 置換ピリジンおよび使用方法

Country Status (23)

Country Link
US (1) US10047051B2 (cg-RX-API-DMAC7.html)
EP (1) EP3303294A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018516932A (cg-RX-API-DMAC7.html)
KR (1) KR20180029204A (cg-RX-API-DMAC7.html)
CN (1) CN107922338A (cg-RX-API-DMAC7.html)
AR (1) AR106865A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016272702A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017026132A2 (cg-RX-API-DMAC7.html)
CA (1) CA2988046A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017003067A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017012566A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170595A (cg-RX-API-DMAC7.html)
DO (1) DOP2017000278A (cg-RX-API-DMAC7.html)
EC (1) ECSP17085494A (cg-RX-API-DMAC7.html)
HK (1) HK1253581A1 (cg-RX-API-DMAC7.html)
IL (1) IL256032A (cg-RX-API-DMAC7.html)
MX (1) MX2017015591A (cg-RX-API-DMAC7.html)
PE (1) PE20180457A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017502201A1 (cg-RX-API-DMAC7.html)
RU (1) RU2017146661A (cg-RX-API-DMAC7.html)
TW (1) TW201713621A (cg-RX-API-DMAC7.html)
UY (1) UY36702A (cg-RX-API-DMAC7.html)
WO (1) WO2016193812A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210401869A1 (en) * 2015-02-20 2021-12-30 Rosalind Franklin University Of Medicine And Science Antisense Compounds Targeting Genes Associated with Cystic Fibrosis
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
EP3558982A1 (en) 2016-12-20 2019-10-30 AbbVie S.À.R.L. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
US20220127247A1 (en) * 2019-02-06 2022-04-28 Novartis Ag N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
EP3747882A1 (en) 2019-06-03 2020-12-09 AbbVie Overseas S.à r.l. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
TW202115014A (zh) 2019-07-12 2021-04-16 美商奧佛麥德公司 用於治療囊腫纖維化之化合物
US20220211692A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
US20220213041A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
EP4387449A1 (en) 2021-08-19 2024-06-26 Syngenta Crop Protection AG Method for controlling diamide resistant pests & compounds therefor
WO2023034946A1 (en) * 2021-09-03 2023-03-09 Genzyme Corporation Indole compounds and uses thereof in the treatement of cystic fibrosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939558B2 (en) 2004-06-04 2011-05-10 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
ME02799B (me) 2004-06-24 2018-01-20 Vertex Pharma Modulatori ATP-vezujućih kasetnih transportera
NZ581419A (en) 2007-05-25 2012-05-25 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
NZ585789A (en) 2007-12-10 2012-03-30 Novartis Ag Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
ES2422741T3 (es) 2007-12-13 2013-09-13 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US8436014B2 (en) 2008-10-23 2013-05-07 Vertex Pharmaceutical Incorporated Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluorormethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihyroquinoline-3-carboxamide
JP5699090B2 (ja) 2008-12-30 2015-04-08 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 嚢胞性線維症膜コンダクタンス調節因子のモジュレーター
US8247436B2 (en) * 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2760463B1 (en) 2011-09-20 2018-11-21 The University of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
US9382254B2 (en) * 2013-05-07 2016-07-05 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
ES2691944T3 (es) 2013-08-08 2018-11-29 Galapagos Nv Tieno[2,3-c]piranos como moduladores CFTR
CA2942387A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr actvity
EP3116501A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2017196843A1 (en) * 2016-05-09 2017-11-16 Proteostasis Therapeutics, Inc. Methods of identifying cftr modulators

Similar Documents

Publication Publication Date Title
JP2018516932A5 (cg-RX-API-DMAC7.html)
RU2017146661A (ru) Замещенные пиридины и способ их применения
RU2015143917A (ru) Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний
JP2014521696A5 (cg-RX-API-DMAC7.html)
JP2017530999A5 (cg-RX-API-DMAC7.html)
RU2011127402A (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
CN1902196B (zh) 噻唑衍生物
RU2017116598A (ru) Соединения и композиции для модуляции киназной активности мутантов egfr
JP5518838B2 (ja) ピロリジノングルコキナーゼアクチベーター
RU2347777C2 (ru) Двойные агонисты nk1/nk3 для лечения шизофрении
JP2015529192A5 (cg-RX-API-DMAC7.html)
AU2014291711B2 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
JP2018524343A5 (cg-RX-API-DMAC7.html)
JP2005523901A5 (cg-RX-API-DMAC7.html)
RU2011127232A (ru) Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний
HRP20230294T1 (hr) Modulatori tmem16a
RU2001126337A (ru) Соединения, пригодные в качестве противовоспалительных агентов
JP2012532888A5 (cg-RX-API-DMAC7.html)
JP6074043B2 (ja) 新規なモルホリン誘導体またはその塩
HRP20240297T1 (hr) Derivati alfa-d-galaktopiranozida
CN109923113A (zh) 作为GABA A α5 PAM的新型异噁唑基醚衍生物
JP2018512408A5 (cg-RX-API-DMAC7.html)
JP2018505145A5 (cg-RX-API-DMAC7.html)
JPWO2021081375A5 (cg-RX-API-DMAC7.html)
JP2017512806A5 (cg-RX-API-DMAC7.html)